Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | QRFPR | Q96P65 | 4/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630682 | 0.97 | CTSB (0.51) | CTSBQRFPRMMEOPRM1OPRD1 | |
| SCHEMBL29591605 | 0.91 | OPRD1 (0.51) | CTSBQRFPROPRM1OPRD1OPRK1 | |
| SCHEMBL29504883 | 0.90 | NAALAD2 (0.55) | CTSBQRFPRMMEBACE1NAALAD2 | |
| SCHEMBL23142823 | 0.89 | CTSB (0.55) | CTSBQRFPRMMEOPRM1OPRD1 | |
| SCHEMBL30051480 | 0.89 | CTSB (0.55) | CTSBQRFPRMMEOPRM1OPRD1 | |
| SCHEMBL23142822 | 0.89 | CTSB (0.55) | CTSBQRFPRMMEOPRM1OPRD1 | |
| SCHEMBL30051999 | 0.89 | CTSB (0.55) | CTSBQRFPRMMEOPRM1OPRD1 | |
| SCHEMBL31514370 | 0.87 | MME (0.53) | MMEPTPN1ALDH1A1RAB9ANAALAD2 | |
| SCHEMBL29574387 | 0.87 | MME (0.56) | MMENAALAD2 | |
| SCHEMBL27450014 | 0.87 | MME (0.56) | MMENAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | CTSB 2062/4885QRFPR 859/4885MME 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.